1 - 10 of 500
Jeevandhara Sanjeevani generic stores a big hit, benefit Rs.2 cr to patients A Raju Hyderabad Monday, February 18, 2013, 08:00 Hrs [IST] The chain of Jeevandhara Sanjeevani Pharmacy generic drug stores launched with the support of the state government are yet to spread to all over the state. Yet, these generic stores have helped to save up to Rs.2 crore to the patients in the state so far. The Jeevandhara generic outlets have turned out to be a big hit among the poor patients and have...
Premium Pharmaceutical industry, Food and Drug Administration, Andhra Pradesh 757 Words | 4 Pages
Open Documentcoupled with free blood pressure check-up and full 20% discount in all branches 1949- THEGENERICSPHARMACY stemmed from its mother company 1959-the company began importing and wholesaling pharmaceutical products. 1989-the company decided to sell generic drugs primarily to government hospitals 2001- the company stepped up its distribution by opening its retail arm 2007, THEGENERICSPHARMACY tapped Francorp, the world leader in franchising, to engineer its franchise development and growth 2008- 150...
Premium Inventory, Electronic Data Interchange, Generic drug 1351 Words | 6 Pages
Open Documentfirms focus primarily on branded generic final formulations using imported APIs. Branded generics are a category of drugs including prescription products that are either novel dosage forms of off-patent products produced by a manufacturer that is not the originator of the molecule, or a molecule copy of an off-patent product with a trade name. About 80% of the drugs sold in Bangladesh are generics and 20% are patented drugs. The country manufactures about 450 generic drugs for 5,300 registered brands...
Premium Pharmaceutical industry, World Trade Organization, Patent law 798 Words | 4 Pages
Open Documentproducts are off-patent drugs that are manufactured and distributed without licensing from the original manufacturer because the patents on such drugs have expired. In December 2005, Ranbaxy's shares were hit hard by a patent ruling disallowing production of its own version of Pfizer's cholesterol-cutting drug Lipitor, which has annual sales of more than $10 billion.[3] In June 2008, Ranbaxy settled the patent dispute with Pfizer allowing them to sell Atorvastatin Calcium, the generic version of Lipitor(R)and...
Premium Simvastatin, Teva Pharmaceutical Industries, Dr. Reddy's Laboratories 630 Words | 3 Pages
Open Documentcolluding to keep a generic painkiller off the market. As presented in the article "Novartis, J&J Face EU Antitrust Investigation" (Whalen, 2011), "In markets where J&J's patents on Fentanyl have expired, Novartis's generic-drug unit Sandoz sells low-cost copies of the drug". Upon expiration of the patent that J&J issued to the generic provider, the company opted to allow Novartis' generic drug unit Sandoz to sell low-cost copies of the drug instead of reengaging the generic provider. The article...
Premium Competition, Tying, Sherman Antitrust Act 1350 Words | 6 Pages
Open Documentrelates: Candidate name: Sushmi Dey | New Delhi March 30, 2013 Govt begins work on 3 more compulsory licences DIPP wants foolproof case on anti-cancer drugs of Roche, Bristol-Myers The department of industrial policy and promotion is actively considering the grant of compulsory licences for three new anti-cancer drugs. The department, a wing of the commerce ministry, which also looks at intellectual property-related issues, has sought details regarding prices, efficacy levels and...
Free Generic drug, Bristol-Myers Squibb, Patent law 1170 Words | 5 Pages
Open Documentglobal operations is determined into generic molecules and does not aim to venture into other areas. While in domestic market it has taken conventional route of branded products with it seven brands enjoying good market share. Ranbaxy also makes it difficult for new or potential entrants to enter its segment as it is eschewing the highly competitive segments of the market. Moreover the skills required in its product line are not easy to acquire. The choice of generic molecules in its global operations...
Premium Ranbaxy Laboratories, Marketing, Strategic management 715 Words | 3 Pages
Open Documentmanufacturing industry among the developing countries. Presently, the industry meets 97% of local demand and exports to more than 80 countries. The industry has been experiencing robust growth over the last few years. A local industry supporting drug policy and effective regulatory framework, along with TRIPS relaxations are the key reasons for success of the industry. While the industry is achieving self-sufficiency, it yet procures 70% of raw materials from abroad. But developments are already...
Premium Pharmacology, GlaxoSmithKline, AstraZeneca 1573 Words | 7 Pages
Open Documenttransparency about drugs and price policy. Thus, the companies will have to face with pressure on customer service. Eventually, the market is likely to grow with increasing health concerns like the obesity issue which has become crucial in Western countries for the past decade. Legal: The market lives with many regulatory and legislative restrictions, particularly about ethics. Companies also tackle with the issue of intellectual property rights and the generic drugs. Moreover, they...
Premium Pharmacology, Medicine, Developing country 1158 Words | 5 Pages
Open DocumentBiocon: Launching a New Cancer Drug in India Section E Group 5 Ankita Khandelwal (255) Bojja Raghavendar Reddy (265) Hitesh Chopra (275) Nikhil Singh Rawat (285) Raghavan K. V. (295) Vaibhav Saxena (305) Situation Analysis: • Biocon is an Indian Drug company that has evolved over the years: ▪ It was an enzyme manufacturer for food industry and developed expertise...
Premium Cancer, Pharmacology, Generic drug 987 Words | 6 Pages
Open Document